Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Paco Darcos, Portugal Clinical Trials

A listing of Paco Darcos, Portugal clinical trials actively recruiting patients volunteers.

RESULTS

Found (22) clinical trials

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer

A Phase 2, open-label, multicenter international study will be performed to evaluate the efficacy of MCLA-128-based combinations. Three combination treatments will be evaluated, two in Cohort 1 and one in Cohort 2. MCLA-128 is given in combinations in two metastatic breast cancer (MBC) populations, HER2-positive/amplified (Cohort 1) and Estrogen Receptor-positive/low ...

Phase

4.19 miles

Learn More »

An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

This Phase II, multicenter, open-label extension (OLE) study will evaluate the long-term safety and efficacy of GDC-0853 in participants with systemic lupus erythematosus (SLE) who have completed Study GA30044 (NCT02908100) up to 48 weeks.

Phase

4.57 miles

Learn More »

Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects

Clinical Trial looking to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas aeruginosa

Phase

6.41 miles

Learn More »

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other agents in a Genentech/Roche-sponsored parent study who are active and deriving benefit at the closure of parent study are eligible for continued treatment in this study.

Phase

6.66 miles

Learn More »

Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN)

To characterize dose response, and evaluate safety and efficacy of three different doses of EMA401 compared to placebo in patients with post-herpetic neuralgia (PHN)

Phase

6.66 miles

Learn More »

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF

The primary hypothesis in this trial is that the treatment with vericiguat 10 mg or 15 mg in patients with HFpEF improves the KCCQ PLS (Kansas City Cardiomyopathy Questionnaire Physical limitation score) compared to placebo after 24 weeks of treatment.

Phase

6.66 miles

Learn More »

Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

This study will determine the dose-response relationship of VAY736 for key efficacy and safety parameters

Phase

6.96 miles

Learn More »

Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)

The purpose of this study is to evaluate safety and efficacy of EMA401 compared to placebo in patients with painful diabetic neuropathy (PDN).

Phase

7.74 miles

Learn More »

An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis

The main objectives of this trial are to evaluate the long term efficacy and safety of different doses of BI 655064 versus placebo as add-on therapy to Standard of Care (SOC) during maintenance therapy for lupus nephritis.

Phase

7.89 miles

Learn More »

Dose Finding Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis

The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the dose-response relationship within the therapeutic range, and select the target dose for ...

Phase

8.4 miles

Learn More »